THE BUSINESS OF BIOTECH
A Royalty Model For Value Creation With Zymeworks' Kenneth Galbraith
On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through partnerships with companies including Jazz Pharmaceuticals and BeOne Med...
ABOUT THE BUSINESS OF BIOTECH
Created exclusively for the leaders of new and emerging biopharma firms, The Business of Biotech tackles organizational, funding, HR, regulatory, production and CMC considerations with insight from peer founders who have taken biologic therapies from an idea to clinical success.
MEET YOUR HOST
Ben Comer is chief editor of Life Science Leader magazine. He has covered the biopharmaceutical, medtech and medical device industries for 15 years as a reporter and editor, and worked as a senior manager in PwC’s Health Research Institute.
Interested in joining us on air? Contact us
THE BUSINESS OF BIOTECH PODCAST
FINANCE & CAPITAL MARKETS
DISCOVERY/R&D
